[go: up one dir, main page]

NO2019008I1 - Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav - Google Patents

Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav

Info

Publication number
NO2019008I1
NO2019008I1 NO2019008C NO2019008C NO2019008I1 NO 2019008 I1 NO2019008 I1 NO 2019008I1 NO 2019008 C NO2019008 C NO 2019008C NO 2019008 C NO2019008 C NO 2019008C NO 2019008 I1 NO2019008 I1 NO 2019008I1
Authority
NO
Norway
Prior art keywords
lesinurad
allopurinol
salts
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO2019008C
Other languages
English (en)
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2019008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of NO2019008I1 publication Critical patent/NO2019008I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO2019008C 2010-06-15 2019-02-19 Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav NO2019008I1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (1)

Publication Number Publication Date
NO2019008I1 true NO2019008I1 (no) 2019-02-19

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2019008C NO2019008I1 (no) 2010-06-15 2019-02-19 Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav

Country Status (19)

Country Link
US (3) US9216179B2 (no)
EP (1) EP2582683B1 (no)
JP (1) JP5964821B2 (no)
CA (1) CA2802407C (no)
CY (1) CY1120473T1 (no)
DK (1) DK2582683T3 (no)
ES (1) ES2670700T3 (no)
HR (1) HRP20180780T1 (no)
HU (1) HUE038265T2 (no)
LT (1) LT2582683T (no)
NO (1) NO2019008I1 (no)
PL (1) PL2582683T3 (no)
PT (1) PT2582683T (no)
RS (1) RS57275B1 (no)
SI (1) SI2582683T1 (no)
SM (1) SMT201800266T1 (no)
TR (1) TR201806828T4 (no)
WO (1) WO2011159732A1 (no)
ZA (1) ZA201300055B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3659601A1 (en) 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
CN106963761A (zh) * 2011-11-03 2017-07-21 阿迪亚生命科学公司 3,4‑二取代的吡啶化合物、其使用方法以及包含该化合物的组合物
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
EA038828B9 (ru) * 2015-12-08 2021-12-03 Ардеа Байосаенсез, Инк. Фармацевтическая композиция, содержащая действенный ингибитор urat1
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
CA3060185A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060211A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CN114341120A (zh) * 2019-08-21 2022-04-12 国立大学法人东京大学 Abcc11抑制剂
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914611B2 (ja) 2003-12-26 2012-04-11 キッセイ薬品工業株式会社 ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
SG155246A1 (en) 2004-08-25 2009-09-30 Ardea Biosciences Inc S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
BRPI0806608A2 (pt) 2007-01-19 2011-09-06 Takeda Pharmaceuticals North America Inc métodos para prevenir ou reduzir o número de surtos agudos de gota utilizando inibidores xantina oxidoredutase e agentes anti-inflamatórios
AR069753A1 (es) 2007-11-27 2010-02-17 Ardea Biosciences Inc Compuestos de 1,2,4-triazol y composiciones, utiles en la modulacion de los niveles de acido urico sanguineo
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
KR101294872B1 (ko) 2008-09-04 2013-08-08 아디아 바이오사이언스즈 인크. 요산 수치를 조절하기 위한 화합물, 조성물 및 이들의 사용 방법
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010135530A2 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
JP5696346B2 (ja) 2010-01-08 2015-04-08 アルデア バイオサイエンシーズ インク． ナトリウム２−（５−ブロモ−４−（４−シクロプロピルナフタレン−１−イル）−４ｈ−１，２，４−トリアゾル−３−イルチオ）アセテートの多形性、結晶性、および、中間相の形態と、その使用
EP3659601A1 (en) 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
EP2588110B1 (en) * 2010-07-02 2018-10-17 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012050589A1 (en) 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
EA022301B1 (ru) 2010-12-30 2015-12-30 Ардеа Биосайнсиз, Инк. Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение
JP5964952B2 (ja) 2011-05-24 2016-08-03 アルデア バイオサイエンシーズ インク． 高血圧症と高尿酸血症

Also Published As

Publication number Publication date
CA2802407C (en) 2018-01-23
ZA201300055B (en) 2018-05-30
HUE038265T2 (hu) 2018-10-29
US20190015392A1 (en) 2019-01-17
DK2582683T3 (en) 2018-06-06
US9216179B2 (en) 2015-12-22
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
SMT201800266T1 (it) 2018-07-17
SI2582683T1 (en) 2018-07-31
EP2582683A1 (en) 2013-04-24
CA2802407A1 (en) 2011-12-22
ES2670700T3 (es) 2018-05-31
PL2582683T3 (pl) 2018-08-31
EP2582683B1 (en) 2018-03-21
EP2582683A4 (en) 2014-04-30
TR201806828T4 (tr) 2018-06-21
JP2013528650A (ja) 2013-07-11
CY1120473T1 (el) 2019-07-10
PT2582683T (pt) 2018-05-25
JP5964821B2 (ja) 2016-08-03
WO2011159732A1 (en) 2011-12-22
HRP20180780T1 (hr) 2018-07-13
RS57275B1 (sr) 2018-08-31
US20160143889A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
NO2019008I1 (no) Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav
NO2021033I1 (no) Selineksor eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2020047I1 (no) Remdesivir eller et farmasøytisk akseptabelt salt eller ester derav
NO2025011I1 (no) Erdafitinib or a pharmaceutically acceptable salt thereof or a solvate thereof
NO2022031I1 (no) Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NO2017057I2 (no) pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2021040I1 (no) glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2023023I1 (no) Maralixibat, or a pharmaceutically acceptable salt thereof, in particular maralixibat chloride
NO2023032I1 (en) Deucravacitinib or a pharmaceutically acceptable salt thereof
NO2020001I1 (no) Gilteritinib eller et salt derav
NL301157I2 (nl) odevixibat of een farmaceutisch aanvaardbaar zout daarvan
FIC20240012I1 (fi) Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2017059I2 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2018026I1 (no) Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir
NO2019010I1 (no) Eravasyklin eller farmasøytisk akseptable salter derav